PARP inhibitors: a proven class facing limits
Jules Adam
Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers. The post PARP inhibitors: a proven class facing limits appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu